|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer(TH3RESA) : a randomised, open-label, phase 3 trial显示文摘 | Krop IE Kim SB Gonz61ez-Martin A | 2014 | Lancet Oncel2014，15，7： | 1 |
| 2 | A putative role for psoriasin in breast tumor progression显示文摘 | Krop I M(a)rz A Carlsson H | | 0，，24： | 1 |
| 3 | Ofloxacin:why the increased popularity 显示文摘 | Krop LC | 1996 | J Pharm Technol1996，12，1： | 1 |
| 4 | Phase I study of trasmzum- ab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive meta static breast cancer显示文摘 | Krop IE Beeram M Modi S | 2010 | J Clin Oncol2010，28，16： | 1 |
| 5 | Partition constants of chlorinated dibenzofurans and dibenzo-p-dioxins显示文摘 | HARRIE A J COVERS H KROP B | 1998 | Chemosphere1998，37，9： | 1 |
| 6 | A sage view of breast tumor progression显示文摘 | Porter DA Krop IE Nasser S | 2001 | Cancer Res2001，61，15： | 1 |
| 7 | Assessment of the durability of concrete from its permeation properties: a review显示文摘 | Basheer L Krop PJ Cleland D J | 2001 | Construction and Building Materials2001，15，2： | 1 |
| 8 | A phase II study of trastu- zumab emtansine in patients with human epidermal growth factor receptor 2 - positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine显示文摘 | Krop I E LoRusso P Miller K D | 2012 | J Clin Oncol2012，30，26： | 1 |
| 9 | HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells显示文摘 | Krop 1E Sgroi D Porter DA | 2001 | Proc Natl Acad Sci2001，98，17： | 1 |
| 10 | Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy显示文摘 | Partridge D Krop I E Garber J E | 2007 | Surg Oncol2007，96，6： | 1 |
| 11 | Assessment of safety and activity in an expanded phase 1 study of MM -302, a HER2 -targeted liposomal dox- ombicin, in patients with advanced HER2 -positive (HER2 + ) breast cancer 显示文摘 | Munster P Krop L Miller K | 2013 | Cancer Res2013，73，41： | 1 |
| 12 | Advances in targeting SRC in the treatment of breast cancer and other solid malignancies 显示文摘 | Mayer EL Krop IE | 2010 | Clin Cancer Res2010，16，14： | 1 |
| 13 | A SAGE view of breast tumor progression显示文摘 | Porter DA Krop IE Nasser S | 2001 | Cancer Res2001，61，15： | 1 |
| 14 | Searching for early breast cancer biomarkers by serum protein profilingof pre-diagnostic serum;a nested case-control study显示文摘 | OPSTAL-VAN WINDEN A W KROP E J KAREDAL M H | 2011 | BMC Cancer2011，11，： | 1 |
| 15 | Phase I study of trastuzumab-DM1,a HER-2 antibody-drug conjugate,given every 3 weeks to patients with HER-2-positive metastatic breast cancer显示文摘 | Krop IE Beeram M Modi S | | 0，，16： | 1 |
| 16 | HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells显示文摘 | Krop I Maguire P Lahti-Domenici J | 2001 | Proc Natl Acad Sci USA2001，98，17： | 1 |
| 17 | HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells 显示文摘 | Krop I E Sgroi D Porter D A | 2001 | Proc Natl Acad Sci2001，，98： | 1 |
| 18 | HIN-1, an inhibitor of cell growth, invasion, and AKT activation显示文摘 | Krop I Parker MT Bloushtain-Qimron N | 2005 | Cancer Res2005，65，21： | 1 |
| 19 | A SAGE (serial analysis of gene expression) view of breast tumor prcgression显示文摘 | Porter DA Krop IE Nasser S | 2001 | Cancer Res2001，61，15： | 1 |
| 20 | Swimming pool atendance and respiratory symptoms and allergies among Dutch children显示文摘 | Jacobs JB Fuertes E Krop EJ | 2012 | Occup Environ Med2012，69，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员